Core Viewpoint - Freshpet, Inc. is under investigation for potential violations of federal securities laws following misleading advertising claims about its dog food products, which has led to a significant drop in its stock price [1][2][3]. Group 1: Investigation and Legal Actions - Kessler Topaz Meltzer & Check, LLP is investigating Freshpet, Inc. on behalf of investors who experienced financial losses after purchasing its securities [1]. - The investigation is prompted by findings from the BBB National Programs' National Advertising Division that Freshpet's advertisements misled consumers regarding the quality of its dog food [2]. Group 2: Stock Performance - Following the news of the misleading advertisements, Freshpet's stock price fell by $7.95 per share, a decline of nearly 11%, closing at $67.42 on March 17, 2026, down from $75.37 on March 16, 2026 [3]. Group 3: Company Background - Kessler Topaz Meltzer & Check, LLP is a prominent U.S. law firm specializing in securities-fraud class actions and has recovered over $25 billion for clients [5].

Core Viewpoint - G-III Apparel Group's reported GAAP earnings per share (EPS) of $1.51 significantly diverged from the previously guided range of $2.72-$2.82, leading to an 11.4% drop in share value, prompting potential legal action from investors [1][2]. Financial Performance - The company guided full-year GAAP EPS to be between $2.72 and $2.82, while the actual reported GAAP EPS was $1.51, resulting in a discrepancy of at least $1.21 per share, which represents a divergence of approximately 44-45% [2]. - The reported figures included $45 million in fourth-quarter non-cash impairment charges, which were not disclosed in the management's projections to investors [3].

Core Viewpoint - IperionX Limited is under investigation for potential violations of federal securities laws, which may impact investors who have incurred losses [1] Group 1: Company Overview - IperionX Limited is listed on NASDAQ under the ticker symbol IPX [1] - The investigation is being conducted by Glancy Prongay Wolke & Rotter LLP, a prominent national shareholder rights law firm [1] Group 2: Investor Implications - Investors who have lost money on IperionX Limited are encouraged to inquire about pursuing claims to recover their losses [1]

Core Viewpoint - The Soleno Therapeutics, Inc. is facing a class action lawsuit due to alleged violations of the Securities Exchange Act of 1934, primarily related to the safety and commercial viability of its product DCCR for treating hyperphagia in Prader-Willi syndrome patients [1][3]. Company Overview - Soleno Therapeutics is a biopharmaceutical company focused on developing therapeutics for rare diseases, with its only commercial product being diazoxide choline extended-release tablets (DCCR) [2]. Allegations of the Lawsuit - The lawsuit claims that Soleno and its executives failed to disclose significant safety concerns related to DCCR, including issues of excess fluid retention in clinical trial participants [3]. - It is alleged that the administration of DCCR posed greater safety risks than disclosed, leading to lower commercial viability and undisclosed risks such as patient discontinuation rates and prescriber reluctance [3]. Impact of External Reports - On August 15, 2025, a critical report by Scorpion Capital LLC led to a nearly 12% decline in Soleno's stock price over two trading days [4]. - Following a report of a patient death associated with DCCR on September 10, 2025, Soleno's stock price dropped approximately 19% over two trading days [5]. - The financial results reported on November 4, 2025, indicated a "disruption" in DCCR's launch trajectory, resulting in a further 27% decline in stock price [6]. Legal Process - Investors who purchased Soleno common stock during the class period can seek appointment as lead plaintiff in the class action lawsuit, which allows them to act on behalf of other class members [7]. - Serving as lead plaintiff is not a requirement for sharing in any potential recovery from the lawsuit [8]. Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm in securities fraud and shareholder rights litigation, having recovered over $916 million for investors in 2025 alone [9].

Camping World Holdings, Inc. (CWH) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit Accessibility StatementSkip NavigationBENSALEM, Pa., March 18, 2026 /PRNewswire/ -- The Law Offices of Howard G. Smithannounces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Camping World Holdings, Inc. ("Camping World" or the "Company") (NYSE: CWH).IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN CAMPING WORLD HOLDINGS, INC. (CWH), ...

Core Viewpoint - The Boston Scientific Corporation is facing a class action lawsuit for alleged violations of the Securities Exchange Act of 1934, with claims that the company misled investors regarding its revenue outlook and market share growth during a specified class period [1][3]. Group 1: Class Action Details - The class action lawsuit is titled Troike v. Boston Scientific Corporation, and it includes purchasers of Boston Scientific common stock from July 23, 2025, to February 3, 2026 [1]. - Investors have until May 4, 2026, to seek appointment as lead plaintiff in the lawsuit [1]. - The lawsuit alleges that Boston Scientific and its executives made false statements and failed to disclose critical information about the company's financial health and market competition [3]. Group 2: Financial Performance - On February 4, 2026, Boston Scientific reported its fourth quarter and full year 2025 financial results, showing a GAAP net income of $672 million or $0.45 per share for Q4 2025, compared to $566 million or $0.38 per share a year ago [4]. - For the full year 2025, the company reported a GAAP net income of $2.898 billion or $1.94 per share, up from $1.853 billion or $1.25 per share the previous year [4]. - The adjusted EPS for Q4 2025 was $0.80, compared to $0.70 a year ago, and for the full year, it was $3.06, compared to $2.51 a year ago [4]. - Following the financial results announcement, Boston Scientific's stock price fell by more than 17% [4]. Group 3: Legal Process and Representation - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Boston Scientific common stock during the class period to seek lead plaintiff status [5]. - The lead plaintiff will represent the interests of all class members and can choose a law firm to litigate the case [5]. - An investor's potential recovery is not contingent upon serving as lead plaintiff [5]. Group 4: Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder rights litigation, having recovered over $916 million for investors in 2025 alone [6]. - The firm has a strong track record, recovering $8.4 billion for investors over the past five years, significantly more than any other law firm [6].

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of common stock of Gartner, Inc. (NYSE: IT) for the period between February 4, 2025, and February 2, 2026, due to alleged securities fraud [1]. Group 1: Lawsuit Details - The lawsuit claims that Gartner made false and misleading statements regarding its growth rates and was not adequately prepared to meet consulting revenue targets or maintain its contract value (CV) growth rate [5]. - Gartner's assertions of achieving 12-16% CV growth rates in a normal macroeconomic environment were deemed unrealistic, leading to investor damages when the true situation was revealed [5]. Group 2: Participation Information - Investors who purchased Gartner common stock during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, interested parties can visit the provided link or contact Rosen Law Firm directly for more information [3][6].

Core Viewpoint - Nektar Therapeutics is facing a class action lawsuit due to alleged securities fraud, with a deadline for shareholders to file a lead plaintiff motion by May 5, 2026 [1][4]. Group 1: Lawsuit Details - The lawsuit is based on claims that Nektar made materially false and misleading statements regarding its business and the results of the Phase 2b REZOLVE-AA trial for its alopecia areata treatment, rezpegaldesleukin [3]. - The trial results announced on December 16, 2025, indicated a failure to reach statistical significance, attributed to the inclusion of ineligible patients [2][3]. - Following the announcement, Nektar's stock price dropped by $4.14, or 7.8%, closing at $49.16 per share [3]. Group 2: Investor Participation - Investors who purchased Nektar securities between February 26, 2025, and December 15, 2025, are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights and potentially participate in the class action [1][2][4]. - To be appointed as lead plaintiff, investors must meet certain legal requirements and must file their motion by the specified deadline [4].

Core Viewpoint - BFA Law is investigating Tennant Company for potential violations of federal securities laws following a 23% drop in its stock price due to issues with its ERP system [1][2]. Company Overview - Tennant Company manufactures industrial cleaning equipment, including large mechanical floor scrubbers and sweepers used in various commercial facilities [2]. Investigation Details - The investigation focuses on whether Tennant made false and misleading statements regarding the implementation and rollout of its ERP system, claiming it was "on time and on budget" and that the launch in the Asia-Pacific region was "successful" [3]. - On February 24, 2026, Tennant disclosed that the ERP rollout in North America caused significant operational disruptions, leading to an inability to process and ship customer orders, resulting in an estimated loss of $30 million in sales and an increased remediation cost of over $20 million for 2026, compared to the planned $5 million [3][4]. Stock Performance - Following the announcement of the ERP issues, Tennant's stock price fell by $19.28 per share, a decline of more than 23%, from a closing price of $82.30 on February 23, 2026, to $63.02 on February 24, 2026 [4][5].

Core Viewpoint - A securities fraud class action lawsuit has been filed against ChowChow Cloud International Holdings Limited (CHOW) on behalf of investors who acquired CHOW securities between September 16, 2025, and December 10, 2025, due to alleged market manipulation and misleading statements by the company [1][4]. Summary by Sections Company Background - ChowChow Cloud International Holdings Limited (CHOW) conducted its initial public offering (IPO) on September 16, 2025, selling 2.6 million ordinary shares at $4.00 per share [2]. Allegations of Fraud - The lawsuit claims that CHOW was subject to a market manipulation scheme that involved impersonators posing as financial advisors, which misled investors and created a buying frenzy [3][4]. - On December 10, 2025, CHOW's stock price plummeted by $9.87, or 84.3%, closing at $1.83 per share, following the revelation of the manipulation scheme [3]. Misleading Statements - The complaint alleges that CHOW made materially false and misleading statements and failed to disclose significant risks related to its business and operations, including: - The existence of a market manipulation scheme [4]. - Omission of risks associated with fraudulent trading and market manipulation [5]. - The unique risk of trading suspension and volatility due to the manipulation [5]. - The underwriter of the IPO, Tiger Securities, had prior regulatory issues with FINRA [5]. Legal Proceedings - Investors who purchased CHOW securities during the class period have until May 12, 2026, to file a lead plaintiff motion in the class action lawsuit [1][6].